- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/76 - Albumines
Détention brevets de la classe C07K 14/76
Brevets de cette classe: 420
Historique des publications depuis 10 ans
|
38
|
22
|
43
|
34
|
33
|
45
|
28
|
23
|
30
|
27
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| EpiVax, Inc. | 80 |
16 |
| Perfect Day, Inc. | 56 |
12 |
| Neutrolis, Inc. | 33 |
12 |
| Bioverativ Therapeutics Inc. | 214 |
11 |
| Zymeworks Inc. | 264 |
8 |
| Sanofi Aatd Inc. | 17 |
8 |
| CSL Behring GmbH | 346 |
6 |
| Sartorius Albumedix Limited | 47 |
6 |
| Centre National de La Recherche Scientifique | 10706 |
5 |
| Ablynx N.V. | 402 |
5 |
| Hamlet Pharma AB | 18 |
5 |
| Medicenna Therapeutics Inc. | 39 |
5 |
| Keros Therapeutics, Inc. | 71 |
5 |
| Invitria, Inc. | 42 |
5 |
| Massachusetts Institute of Technology | 10150 |
4 |
| Mayo Foundation for Medical Education and Research | 3295 |
4 |
| The Brigham and Women's Hospital, Inc. | 2227 |
4 |
| Georgia State University Research Foundation, Inc. | 351 |
4 |
| Jubilant DraxImage Inc. | 146 |
4 |
| Regents of the University of Minnesota | 2739 |
4 |
| Autres propriétaires | 287 |